- Q3 2026 sales $24.4B, adj EPS $7.48.
- Mounjaro sales $10.72B, Zepbound $5.35B.
Eli Lilly beat Q3 sales and profit estimates. Mounjaro and Zepbound drove growth. Foundayo missed Street forecasts. Full-year sales guidance raised to $91-92 billion. EPS view lowered on acquisition charges. CFO says deals are bets for future revenue. Stock jumped 6%.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.